A group of diabetes patients filed a lawsuit Monday against three drug companies for systematically increasing the list prices of insulin for years, in an alleged fraudulent pricing scheme that saddled patients with "crushing out-of-pocket expenses," according to the filing.
The insulin market is dominated by an oligopoly of companies that sell many billions of dollars worth of insulin each year -- and have steadily raised the list prices of their drugs. A version of insulin, called Humalog, launched two decades ago with a sticker price of $21 a vial and has increased to $255 a vial.
